Delta-Fly Pharma, Inc. (JP:4598)
:4598
Want to see JP:4598 full AI Analyst Report?
4598 Stock Chart & Stats
¥507.00
-¥3.00(-0.55%)
At close: 4:00 PM EST
¥507.00
-¥3.00(-0.55%)
Day’s Range― - ―
52-Week Range¥122.00 - ¥793.00
Previous CloseN/A
Volume237.90K
Average Volume (3M)379.72K
Market Cap
¥1.74B
Enterprise Value¥1.55B
Total Cash (Recent Filing)¥730.32M
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.72
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-171.79
Shares Outstanding14,225,000
10 Day Avg. Volume693,770
30 Day Avg. Volume379,723
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)66.43
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Financial LeverageA zero-debt capital structure is a durable strength: it lowers fixed obligations and refinancing risk, giving management flexibility to pursue R&D or partnerships without immediate interest burden. This structural cushion improves resilience when raising funds over the next 2–6 months.
Proprietary Drug Delivery And Oncology FocusOwning proprietary delivery technology and concentrating on oncology creates sustainable competitive advantages: high barriers to entry, differentiated product potential, and attractive licensing or partner interest. These structural attributes support long-term commercial opportunity and strategic partnership value.
Diverse Non-sales Funding OptionsThe company’s articulated ability to monetize via licensing, partnerships, milestone payments, and grants provides durable financing pathways common to clinical-stage biotechs. These options can reduce reliance on equity raises and help fund development through strategic, non-dilutive or milestone-linked capital.
Bears Say
Zero Recent RevenueSustained zero revenue over multiple years is a structural weakness for long-term viability: it eliminates internally generated funding and forces dependency on external capital. For a development-stage biotech this raises execution and funding risk until commercialization or major licensing occurs.
Severe And Persistent Cash BurnConsistent, large negative operating and free cash flow materially increases funding needs and dilution risk. Persistent cash burn without near-term revenue or clear inflection magnifies the probability of repeated capital raises, which can constrain strategic choices and partner negotiations.
Eroded Equity And Asset BaseA collapsing equity and asset base signals deteriorating financial flexibility and increases insolvency risk if losses persist. Shrinking capital limits the company’s ability to weather setbacks, fund trials, or secure favorable partnership terms, weakening long-term operational optionality.
Delta-Fly Pharma, Inc. News
4598 FAQ
What was Delta-Fly Pharma, Inc.’s price range in the past 12 months?
Delta-Fly Pharma, Inc. lowest stock price was ¥122.00 and its highest was ¥793.00 in the past 12 months.
What is Delta-Fly Pharma, Inc.’s market cap?
Delta-Fly Pharma, Inc.’s market cap is ¥1.74B.
When is Delta-Fly Pharma, Inc.’s upcoming earnings report date?
Delta-Fly Pharma, Inc.’s upcoming earnings report date is Aug 07, 2026 which is in 47 days.
How were Delta-Fly Pharma, Inc.’s earnings last quarter?
Delta-Fly Pharma, Inc. released its earnings results on May 15, 2026. The company reported -¥29.73 earnings per share for the quarter, missing the consensus estimate of N/A by -¥29.73.
Is Delta-Fly Pharma, Inc. overvalued?
According to Wall Street analysts Delta-Fly Pharma, Inc.’s price is currently Overvalued.
Does Delta-Fly Pharma, Inc. pay dividends?
Delta-Fly Pharma, Inc. does not currently pay dividends.
What is Delta-Fly Pharma, Inc.’s EPS estimate?
Delta-Fly Pharma, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Delta-Fly Pharma, Inc. have?
Delta-Fly Pharma, Inc. has 14,225,000 shares outstanding.
What happened to Delta-Fly Pharma, Inc.’s price movement after its last earnings report?
Delta-Fly Pharma, Inc. reported an EPS of -¥29.73 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.047%.
Which hedge fund is a major shareholder of Delta-Fly Pharma, Inc.?
Currently, no hedge funds are holding shares in JP:4598
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Delta-Fly Pharma, Inc.
Delta-Fly Pharma, Inc., established in Tokushima, Japan, in 2010, is a biotechnology company focused on the development of innovative oncology drugs. Their comprehensive pipeline includes several drug candidates targeting various cancers. DFP-10917 is currently undergoing Phase III clinical evaluation in the United States and Phase I in Japan for relapsed/refractory acute myeloid leukemia. Another significant compound, DFP-14323, is in Phase III trials for lung cancer. The firm is also advancing DFP-17729 through Phase I/II studies for solid tumors. Furthermore, DFP-11207 has successfully completed its Phase I clinical trial for pancreatic cancer. For hematologic malignancies, DFP-14927 is in Phase I, while DFP-10825 is in preclinical development, targeting gastric and ovarian cancers.